MSMinji Song

Minji Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Minji Song has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Repression of Transcriptional Activity of Forkhead Box O1 by Histone Deacetylase Inhibitors Ameliorates Hyperglycemia in Type 2 Diabetic Rats

    by Hyun Min Cho, Young Mi Seok, Hae Ahm Lee, Minji Song, InKyeom Kim

    Type 2 diabetes mellitus (T2DM) is a chronic disease manifested by hyperglycemia. It is essential to effectively control hyperglycemia to prevent complications of T2DM. Here, we hypothesize that repression of transcriptional activity of forkhead box O1 (FoxO1) via histone deacetylase inhibitors (HDACi) ameliorates hyperglycemia in T2DM rats. Methods: Male Long-Evans Tokushima Otsuka (LETO) and Otsuka Long-Evans Tokushima Fatty (OLETF) rats aged 14 weeks were administered sodium valproate (VPA, 0.71% w/v) dissolved in water for 20 weeks. Electrophoretic mobility shift assay (EMSA) and luciferase assay were performed for elucidation of transcriptional regulation through acetylation of FoxO1 by HDACi. Results: VPA attenuated blood glucose levels in accordance with a decrease in the expression of gluconeogenic genes in hyperglycemic OLETF rats. It has been shown that HDAC class I-specific and HDAC class IIa-specific inhibitors, as well as pan-HDAC inhibitors decrease FoxO1 enrichment at the cis-element of target gene promoters. Mutations in FoxO1 prevent its acetylation, thereby increasing its transcriptional activity. HDAC3 and HDAC4 interact with FoxO1, and knockdown of HDAC3, HDAC4, or their combination increases FoxO1 acetylation, thereby decreasing the expression of gluconeogenic genes. Conclusions: These results indicate that HDACi attenuates the transcriptional activity of FoxO1 by impeding deacetylation, thereby ameliorating hyperglycemia in T2DM rats.


  • PS 16-18 HISTONE DEACETYLASE INHIBITOR CG200745 ATTENUATES CARDIAC HYPERTROPHY AND FIBROSIS IN DOCA-INDUCED HYPERTENSIVE RATS

    by InKyeom Kim, Eunjo Lee, Min-Ji Song, Do Young Lee, Seonggu Ro, Joong Myung Cho

    CG200745 is a novel inhibitor of histone deacetylases (HDACs) initially developed for treatment of pancreatic cancer. Since it is water-soluble, it can be administered by mouth. We hypothesized that the HDAC inhibitor CG200745 attenuates cardiac hypertrophy and fibrosis in deoxycorticosteron acetate (DOCA)-induced hypertensive rats. For establishment of hypertension, 40 mg/kg of DOCA was subcutaneously injected four times weekly into Sprague-Dawley rats. All the rats used in this study including sham group had been uninephrectomizd and allowed to free access to drinking water containing 1% NaCl. Systolic blood pressure was measured by tail-cuff method. Blood chemistry such as sodium, potassium, glucose, triglyceride and cholesterol were analyzed. Sections of heart were visualized after trichrome stain as well as hematoxylin and eosin stain. The expression of not only hypertrophic genes such as Nppa and Nppb, but also fibrotic genes such as collagen-1, -3, ctgf, and fibronectin was measured by quantitative real-time PCR (qRT-PCR). Injection of DOCA increased systolic blood pressure, heart weight and cardiac fibrosis, which was attenuated by CG200745. Neither DOCA nor CG200745 affected body weight, vascular contraction and relaxation responses, and blood chemistry. Injection of DOCA increased expression of both hypertrophic genes and fibrotic genes, which was abrogated by CG200745. These results indicate that CG200745 attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.

  • PS 10-13 HISTONE DEACETYLASE INHIBITION AMELIORATES HYPERGLYCEMIA THROUGH DOWN-REGULATION OF GLUCONEOGENESIS

    by InKyeom Kim, Minji Song, Young Mi Seok, Hae Ahm Lee

    Diabetes mellitus (DM) is a chronic disease manifested by hyperglycemia and dyslipidemia. Histone deacetylase (HDAC) inhibitors have been emerged as new pharmacological approaches in the control of DM. However, the roles for HDAC inhibition in controlling DM are still elusive. We hypothesized that HDAC inhibition ameliorates hyperglycemia through down-regulation of gluconeogenesis in type II diabetic rats. Male normoglycemic Long-Evans-Tokushima-Otsuka (LETO) and hyperglycemic Otsuka Long-Evans Tokushima Fatty (OLETF) rats aged 14 weeks were administered sodium valproate (VPA, 0.71% w/v) dissolved in drinking water for 20 weeks during which the levels of blood glucose were analyzed at 13 and 19 weeks. Blood chemistry such as glycated hemoglobin HbA1c, triglyceride and cholesterol were analyzed. The expression of gluconeogenic genes such as glucose 6-phosphatase, phosphoenolpyruvate carboxykinase, fructose-1,6-biphosphatase and pyruvate carboxylase was measured by quantitative real-time polymerase chain reaction. Acetylation of forkhead box protein O1 (FOXO1), which is a master transcription factor for gluconeogenic genes, was determined by western blot with an anti-acetyl-lysine antibody after immunoprecipitation with an anti-FOXO1 antibody. The levels of blood glucose, HbA1c, triglyceride and cholesterol as well as body weight, were greater in OLETF rats than those in LETO rats. VPA administration attenuated weight gain, blood glucose, HbA1c, triglyceride and cholesterol, as well as the expression of gluconeogenic genes in OLETF rats but not in LETO rats. VPA increased acetylation of FOXO1, decreasing its transcription activity for gluconeogenic genes. These results suggest that HDAC inhibition ameliorates hyperglycemia through down-regulation of gluconeogenesis in type II diabetic rats.